Theresa Heggie - Jun 12, 2024 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role
Director
Signature
/s/ Alane P. Barnes, by power of attorney
Stock symbol
BCRX
Transactions as of
Jun 12, 2024
Transactions value $
-$40,925
Form type
4
Date filed
6/14/2024, 04:25 PM
Previous filing
Jun 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCRX Common Stock Award $0 +6.82K +12.93% $0.00 59.6K Jun 12, 2024 Direct F1
transaction BCRX Common Stock Sale -$40.9K -6.7K -11.25% $6.11 52.9K Jun 14, 2024 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCRX Automatic Stock Option Grant Award $0 +49.9K $0.00 49.9K Jun 12, 2024 Common Stock 49.9K $6.30 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
F2 These shares were sold with the sole purpose of generating sufficient proceeds to cover the tax liability incurred in connection with the vesting of 16,745 Restricted Stock Units on June 13, 2024.
F3 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.08 to $6.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F4 Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.